Shares Outstanding (Quarterly) Chart

Historical Shares Outstanding (Quarterly) Data

View and export this data back to 1999. Start Trial.
Date Value
June 30, 2026 7.31M
March 31, 2026 5.557M
December 31, 2025 5.547M
September 30, 2025 5.264M
June 30, 2025 3.687M
March 31, 2025 0.68M
December 31, 2024 0.2359M
September 30, 2024 5.896M
June 30, 2024 5.704M
March 31, 2024 4.264M
December 31, 2023 4.523M
September 30, 2023 4.523M
June 30, 2023 2.880M
March 31, 2023 2.408M
December 31, 2022 2.240M
September 30, 2022 2.171M
June 30, 2022 1.498M
March 31, 2022 1.034M
December 31, 2021 1.034M
September 30, 2021 1.024M
June 30, 2021 0.8058M
March 31, 2021 0.6787M
December 31, 2020 0.4499M
September 30, 2020 0.3061M
June 30, 2020 0.2849M
Date Value
March 31, 2020 0.2587M
December 31, 2019 0.2587M
September 30, 2019 0.1894M
June 30, 2019 0.0295M
March 31, 2019 0.0012M
December 31, 2018 0.0008M
September 30, 2018 0.0006M
June 30, 2018 0.0003M
March 31, 2018 0.0082M
December 31, 2017 0.0077M
September 30, 2017 0.0046M
June 30, 2017 0.0044M
March 31, 2017 0.0001M
December 31, 2016 0.0029M
September 30, 2016 0.0027M
June 30, 2016 0.0027M
March 31, 2016 0.0018M
December 31, 2015 0.0017M
September 30, 2015 0.0014M
June 30, 2015 0.0013M
March 31, 2015 0.001M
December 31, 2014 0.0009M
September 30, 2014 0.0007M
June 30, 2014 0.0007M
March 31, 2014 0.0007M

Shares Outstanding Definition

The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing shares outstanding over time may be the result of company buybacks. Companies frequently make stock buybacks and retire those buybacks as treasury stock.

Read full definition.

Shares Outstanding (Quarterly) Range, Past 5 Years

View Shares Outstanding (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shares Outstanding (Quarterly) Benchmarks

View Shares Outstanding (Quarterly) Benchmarks
Start Trial
Alnylam Pharmaceuticals, Inc. 133.88M
Ernexa Therapeutics, Inc. 1.17M
ACADIA Pharmaceuticals, Inc. 172.13M
Anika Therapeutics, Inc. 13.38M
Savara, Inc. 205.40M